• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

光动力疗法治疗后发生于息肉样脉络膜血管病变眼中的典型脉络膜新生血管。

Classic choroidal neovascularization developing after photodynamic therapy in eyes with polypoidal choroidal vasculopathy.

机构信息

Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan.

出版信息

Jpn J Ophthalmol. 2011 May;55(3):241-247. doi: 10.1007/s10384-011-0006-6. Epub 2011 May 11.

DOI:10.1007/s10384-011-0006-6
PMID:21559909
Abstract

PURPOSE

To investigate the characteristics of eyes with polypoidal choroidal vasculopathy (PCV) which develop secondary classic choroidal neovascularization (CNV) after photodynamic therapy (PDT).

METHODS

We retrospectively reviewed the records of 64 eyes of 64 PCV patients (43 men, 21 women; mean age ± standard deviation, 72.7 ± 8.6 years), who were followed-up for at least 1 year after the initial PDT. There was no evidence of classic CNV in any of the subject eyes on fluorescein angiography (FA) at the first PDT. Eyes which developed of secondary classic CNV after PDT were classified as the CNV group and the other eyes as the No-CNV group.

RESULTS

Secondary classic CNV developed after PDT in 10 (15.6%) of the 64 eyes. Six patients developed CNV within 1 year after the first PDT. Multivariate logistic regression analysis for the baseline factors related to CNV development, including age, gender, greatest linear dimension, and the lesion components, revealed that in the CNV group the age was significantly younger (p = 0.037) and the incidence of retinal edema was significantly greater (p = 0.041) than in the No-CNV group.

CONCLUSIONS

Secondary classic CNV tends to develop after PDT in PCV eyes in younger patients with retinal edema.

摘要

目的

研究光动力疗法(PDT)后发生继发性典型脉络膜新生血管(CNV)的息肉样脉络膜血管病变(PCV)眼的特征。

方法

我们回顾性分析了 64 只 PCV 眼(43 名男性,21 名女性;平均年龄±标准差,72.7±8.6 岁)的记录,这些患者在初始 PDT 后至少随访 1 年。在最初的 PDT 时,所有受检眼的荧光素血管造影(FA)均无典型 CNV 的证据。在 PDT 后发生继发性典型 CNV 的眼被分为 CNV 组,其他眼为 No-CNV 组。

结果

64 只眼中有 10 只(15.6%)在 PDT 后出现继发性典型 CNV。6 例患者在首次 PDT 后 1 年内出现 CNV。对与 CNV 发展相关的基线因素(包括年龄、性别、最大线性维度和病变成分)进行多变量逻辑回归分析,结果表明 CNV 组的年龄显著较小(p=0.037),视网膜水肿的发生率显著较高(p=0.041)。

结论

在 PDT 后,PCV 眼的继发性典型 CNV 更容易发生在有视网膜水肿的年轻患者中。

相似文献

1
Classic choroidal neovascularization developing after photodynamic therapy in eyes with polypoidal choroidal vasculopathy.光动力疗法治疗后发生于息肉样脉络膜血管病变眼中的典型脉络膜新生血管。
Jpn J Ophthalmol. 2011 May;55(3):241-247. doi: 10.1007/s10384-011-0006-6. Epub 2011 May 11.
2
Polypoidal choroidal vasculopathy appearing as classic choroidal neovascularisation on fluorescein angiography.息肉样脉络膜血管病变在荧光素血管造影中表现为典型的脉络膜新生血管。
Br J Ophthalmol. 2007 Sep;91(9):1152-9. doi: 10.1136/bjo.2006.112318. Epub 2007 Feb 21.
3
[Polypoidal choroidal vasculopathy].[息肉样脉络膜血管病变]
Nippon Ganka Gakkai Zasshi. 2012 Mar;116(3):200-31; discussion 232. doi: 10.4264/numa.71.282.
4
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FINDINGS OF CLASSIC CHOROIDAL NEOVASCULARIZATION IN POLYPOIDAL CHOROIDAL VASCULOPATHY.光学相干断层扫描血管造影在息肉状脉络膜血管病变中的典型脉络膜新生血管的表现。
Retina. 2022 Jan 1;42(1):123-128. doi: 10.1097/IAE.0000000000003264.
5
One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.日本患者年龄相关性黄斑变性和息肉样脉络膜血管病变的光动力疗法一年期疗效
Ophthalmology. 2008 Jan;115(1):141-6. doi: 10.1016/j.ophtha.2007.02.031. Epub 2007 Jun 20.
6
Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization.用于治疗伴有息肉样脉络膜新生血管的新生血管性年龄相关性黄斑变性的选择性光动力疗法
Retina. 2007 Sep;27(7):825-31. doi: 10.1097/IAE.0b013e31804b3f70.
7
Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy.吲哚菁绿血管造影:息肉状脉络膜血管病变的光动力治疗引导
Am J Ophthalmol. 2007 Jul;144(1):7-14. doi: 10.1016/j.ajo.2007.03.014. Epub 2007 Apr 30.
8
Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab.息肉样脉络膜血管病变伪装为对雷珠单抗治疗无反应的新生血管性年龄相关性黄斑变性。
Am J Ophthalmol. 2010 Nov;150(5):666-73. doi: 10.1016/j.ajo.2010.05.035. Epub 2010 Aug 16.
9
Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy.光动力疗法治疗息肉状脉络膜血管病变的 3 年随访结果。
Jpn J Ophthalmol. 2011 Jan;55(1):39-44. doi: 10.1007/s10384-010-0886-x. Epub 2011 Feb 18.
10
Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy.息肉状脉络膜血管病变光动力治疗后的出血并发症
Retina. 2007 Mar;27(3):335-41. doi: 10.1097/01.iae.0000233647.78726.46.

引用本文的文献

1
Ranibizumab alone or in combination with photodynamic therapy vs photodynamic therapy for polypoidal choroidal vasculopathy: a systematic review and Meta-analysis.雷珠单抗单独或联合光动力疗法与光动力疗法治疗息肉样脉络膜血管病变的系统评价和Meta分析。
Int J Ophthalmol. 2015 Oct 18;8(5):1056-66. doi: 10.3980/j.issn.2222-3959.2015.05.36. eCollection 2015.
2
Verteporfin photodynamic therapy combined with intravitreal ranibizumab for polypoidal choroidal vasculopathy controversy concerning long-term followup.维替泊芬光动力疗法联合玻璃体内注射雷珠单抗治疗息肉状脉络膜血管病变:关于长期随访的争议
Case Rep Med. 2012;2012:897097. doi: 10.1155/2012/897097. Epub 2012 Oct 30.

本文引用的文献

1
Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.影响光动力疗法治疗后一年息肉样脉络膜血管病变患者视力预后的因素。
Graefes Arch Clin Exp Ophthalmol. 2010 Sep;248(9):1233-9. doi: 10.1007/s00417-010-1365-2. Epub 2010 Mar 30.
2
Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.光动力疗法联合维替泊芬与玻璃体内贝伐单抗治疗息肉状脉络膜血管病变。
Am J Ophthalmol. 2010 Jun;149(6):947-954.e1. doi: 10.1016/j.ajo.2009.12.038. Epub 2010 Mar 26.
3
Approaches toward combining photodynamic therapy with pharmaceuticals that alter vascular microenvironment.
将光动力疗法与改变血管微环境的药物相结合的方法。
Retina. 2009 Jun;29(6 Suppl):S36-8. doi: 10.1097/IAE.0b013e3181ad25e8.
4
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.雷珠单抗与维替泊芬光动力疗法治疗新生血管性年龄相关性黄斑变性:ANCHOR研究的两年结果
Ophthalmology. 2009 Jan;116(1):57-65.e5. doi: 10.1016/j.ophtha.2008.10.018.
5
Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy.光动力治疗后息肉样脉络膜血管病变的复发
Jpn J Ophthalmol. 2008 Nov-Dec;52(6):457-462. doi: 10.1007/s10384-008-0582-2. Epub 2008 Dec 17.
6
Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment.维替泊芬光动力疗法治疗年龄相关性黄斑变性或息肉样脉络膜血管病变:浆液性视网膜色素上皮脱离存在情况的比较
Br J Ophthalmol. 2008 Dec;92(12):1642-7. doi: 10.1136/bjo.2007.137075. Epub 2008 Sep 9.
7
Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy.息肉状脉络膜血管病变光动力疗法的两年结果
Am J Ophthalmol. 2008 Oct;146(4):513-519. doi: 10.1016/j.ajo.2008.05.025. Epub 2008 Jul 9.
8
Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy.光动力治疗后息肉状脉络膜血管病变的显著血管变化。
Br J Ophthalmol. 2008 Jul;92(7):936-40. doi: 10.1136/bjo.2007.132357.
9
Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy.息肉状脉络膜血管病变光动力疗法的长期结果
Retina. 2008 May;28(5):717-22. doi: 10.1097/IAE.0b013e31816577cb.
10
Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.雷珠单抗联合维替泊芬光动力疗法治疗新生血管性年龄相关性黄斑变性(FOCUS):2年结果
Am J Ophthalmol. 2008 May;145(5):862-74. doi: 10.1016/j.ajo.2007.12.029. Epub 2008 Mar 5.